ABT-869

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

9mo

ABBVPhase 2$300.2B

Carboplatin Phase 2 Results Expected

ABT-869• Advanced or Metastatic Non-Small Cell Lung Cancer125

Nov 15Estimated

00%

Competitive Landscape

0 competitors in Advanced or Metastatic Non-Small Cell Lung Cancer

Drug Information

Target Indication

Advanced or Metastatic Non-Small Cell Lung Cancer

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ABT

ABBOTT LABORATORIES

Related Pipeline

Chronic Kidney Disease on Hemodialysis

Kidney Disease

Chronic Low Back Pain

Mixed Dyslipidemia

Moderate to Severe Chronic, Non-malignant Pain